Gujarat Themis Biosyn Ltd promoter Sachin Patel proposes to acquire up to 5.25 lakh shares worth Rs 20 crore

What Gujarat Themis Biosyn Ltd announced

On 15 July 2026, Gujarat Themis Biosyn Ltd (BSE: 506879) filed a revised disclosure under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing updates a previously submitted notice dated 1 July 2026, which the company now treats as withdrawn. The revised notice, signed by promoter‑acquirer Sachin D. Patel, outlines his intention to acquire equity shares of the company from Pharmaceutical Business Group (India) Limited.

Details of the proposed share acquisition

The price of Rs 382 per share is marginally above the 60‑day volume‑weighted average market price (VWAP) of Rs 380.37, satisfying the requirement that the acquisition price not exceed the VWAP by more than 25 %. The acquirer also declared compliance with all disclosure obligations under Chapter V of the Takeover Regulations for the past three years.

Shareholding impact

Before the proposed transaction, the shareholding pattern was as follows:

• Dr. Sachin Patel – 2,97,200 shares (2.29 % of total share capital)
• Pharmaceutical Business Group (India) Ltd – 5,12,40,000 shares (47.02 %)

If the full 5,25,000 shares are acquired, the post‑transaction holdings would become:

• Dr. Sachin Patel – 3,02,200 shares (2.77 %)
• Pharmaceutical Business Group (India) Ltd – 5,07,15,000 shares (46.54 %)

The acquisition therefore modestly increases the promoter’s stake while slightly reducing the seller’s holding. The filing notes that the actual number of shares acquired may be lower than the maximum disclosed.

Key facts at a glance

Why this matters for investors

The disclosure is a routine compliance requirement under SEBI’s takeover code when a promoter or promoter‑group acquires shares that could affect control. Because the acquisition is limited to 0.5 % of the total share capital, it does not trigger a mandatory open offer, and the existing control structure of the company remains unchanged. However, the incremental increase in the promoter’s holding may be viewed as a sign of confidence in the business, while the modest reduction in the seller’s stake does not materially alter the company’s shareholder composition.

Investors should note that the transaction is still subject to completion; the filing only announces the intention and the terms. The actual number of shares transferred could be lower than the maximum disclosed, and the cash consideration will be realized only upon settlement between 21 July and 31 July 2026.

Conclusion

Gujarat Themis Biosyn Ltd has formally revised its earlier share‑acquisition notice, confirming that promoter Sachin D. Patel intends to buy up to 5.25 lakh shares from a related party for up to Rs 20 crore between 21‑31 July 2026. The deal falls under the SEBI exemption for inter‑se transfers, meaning no open offer is required. Post‑transaction, the promoter’s stake will rise modestly to 2.77 %, while the seller’s holding will dip slightly. The filing does not indicate any further regulatory approvals beyond the standard disclosures.